Assertio
Assertio is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. Established in 1995, the company markets four FDA-approved products: Gralise for managing postherpetic neuralgia, Cambia for treating migraines, Zipsor for relieving mild to moderate acute pain, and Lazanda for managing breakthrough cancer pain.
Top Regions
Top Stages
2 past transactions
Spectrum Pharmaceuticals
Acquisition in 2023
Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company based in Henderson, Nevada, specializing in the development and commercialization of innovative oncology and hematology drug products. Founded in 1987, the company is focused on acquiring and advancing targeted therapies, with notable candidates in its pipeline including ROLONTIS, a long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia, and Poziotinib, an irreversible tyrosine kinase inhibitor for non-small cell lung cancer with specific mutations. Additionally, Spectrum is developing an antibody-interferon fusion molecule aimed at treating relapsed or refractory non-Hodgkin’s lymphoma. The company has established various collaborations, including agreements with Hanmi Pharmaceutical Co. Ltd. and The University of Texas M.D. Anderson Cancer Center, to enhance its research and development efforts. Spectrum Pharmaceuticals was formerly known as NeoTherapeutics, Inc. before rebranding in December 2002.
LGS Foundation
Grant in 2023
LGS Foundation is committed to enhancing the lives of people affected with LGS by promoting research, awareness, education, and family support.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.